Background: The rapid increase in published research poses challenges for healthcare professionals aiming to stay updated. While systematic reviews help synthesize findings, their abundance can overwhelm readers. Umbrella reviews address this by summarizing multiple systematic reviews, offering a comprehensive perspective on specific topics. Methods: This article offers a practical, step-by-step guide for conducting an umbrella review, aimed at researchers and clinicians alike. Results: Umbrella reviews effectively integrate data from systematic reviews, ensuring clearer evidence synthesis. Tools like Rayyan and Covidence streamline processes such as screening and data extraction. Strategies for managing overlapping studies and assessing methodological quality enhance the validity of findings. Conclusion: Umbrella reviews are invaluable for evidence-based decision-making, especially in healthcare. This guide equips researchers and clinicians with a structured approach to navigate and synthesize the growing body of systematic reviews, fostering reliable and actionable insights.
Despite infectious diseases being a significant threat to global health, there are continuing concerns that regulatory authorities do not prioritize therapeutic strategies for infectious diseases with the same urgency as those for oncological or orphan diseases. This study aims to examine the differences in the productivity of drug development and approval procedures between non-infectious and infectious diseases, and to determine the utilization patterns of acceleration programs. All molecules and biologic products approved between January 1, 2015, and December 31, 2024 (N = 464) were subject to a cross-sectional study. Drugs@FDA, the Federal Register, and ClinicalTrials.gov were used as sources of data to establish median Clinical Development Time (CDT), Regulatory Approval Time (RAT), and cumulative Regulatory Review Time (RRT). Kruskal–Wallis tests were used to compare median values (interquartile range, IQR), and chi-square tests were used for proportions. Time-to-event differences were tested using Kaplan–Meier analyses with log-rank testing, and hazard ratios (HRs) were calculated using Cox proportional hazards models. Multivariable logistic regression with interaction terms was used to model Priority Review, Fast Track, Breakthrough Therapy, and Accelerated Approval, reporting adjusted odds ratios (aOR). Of 464 approvals, 65 (14.0%) targeted infectious diseases. Median CDT was 2.76 years (IQR 1.80–4.25) versus 3.46 years (IQR 2.59–4.66; p = 0.003), and median RRT was 3.54 years (IQR 2.58–5.03) versus 4.22 years (IQR 3.24–5.73; p = 0.006) for infectious and non‑infectious drugs, respectively. Nevertheless, infectious agents were approved 58% faster (HR = 1.58; 95% CI 1.15–2.16; p = 0.0047). Infectious disease products were more likely to receive Fast Track (OR = 4.49; 95% CI 2.39–8.70) and Priority Review (OR = 10.69; 95% CI 4.57–29.50) but less likely to obtain Breakthrough Therapy (OR = 0.42; 95% CI 0.28–0.63) or Accelerated Approval (OR = 0.12; 95% CI 0.016–0.56). Infectious disease treatments outpace non-infectious disease treatments in terms of drug development and approval timelines. Nevertheless, they are less frequently utilized in pathways like Accelerated Approval, which are scientifically less applicable to acute-disease endpoints. Therefore, policy reforms should focus on addressing the underlying economic and scientific barriers to anti-infective innovation.
Mentorship in predictive large language models (LLMs) presents both opportunities and risks of inequity if these systems are not designed with care. Mentorship quietly shapes medical careers, yet opportunities for it remain unequal. LLMs can analyze student writing and may reveal potential that exams overlook. This predictive capacity could inform fairer mentorship and direct support to students who need it most, helping build a more equitable medical workforce.
9 April 2026 in SN Comprehensive Clinical Medicine